Email this article 
Possibility of using PCA3 score without prostate massage in urine for diagnosing prostate cancer
- Authors: Musaelyan A.A.1, Nazarov V.D.1, Lapin S.V.1, Pavlova O.N.2, Viktorov D.A.2, Toropovsky А.N.2, Boriskin A.G.1, Reva S.A.1, Petrov S.B.1
-
Affiliations:
- I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
- TestGen
- Issue: Vol 16, No 4 (2020)
- Pages: 82-88
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.12.2020
- URL: https://oncourology.abvpress.ru/oncur/article/view/1352
- DOI: https://doi.org/10.17650/1726-9776-2020-16-4-82-88
- ID: 1352
Cite item
Full Text
Abstract
Background. Prostate cancer holds one of the leading positions among malignant neoplasms in men. One of the most well-studied tumor-specific maskers is the PCA3 score in urine obtained after prostate massage. However, the study of the PCA3 score without prostate massage can significantly simplify the preanalytical phase of the study and minimize discomfort for the patient.
Objective. Investigation of the diagnostic significance of PCA3, determined in urine sediment without prostate massage and its comparison with the PCA3 score after prostate massage.
Materials and methods. The study included 2 groups of patients. In the first group (n = 50), the PCA3 score was assessed without prostate massage, and in the second group (n = 15) PCA3 was assessed in urine obtained before and after massage.
Results. The area under the ROC-curve (AUC) for the PCA3 score without prostate massage was 0.722 (95 % confidence interval 0.579—0.865; p = 0.008). Using the ROC analysis, the threshold value, sensitivity and specificity were determined: 25, 72.41 % (95 % confidence interval 54.28— 85.30 %) and 57.14 % (95 % confidence interval 36.55—75.53 %), respectively. The PCA3 score after massage was found to be more sensitive than without prostate massage. A small volume of material, less than 20 ml, significantly affects the sensitivity of PCA3 without massage.
Conclusion. PCA3 without prostate massage may serve as an option to improve the early diagnosis of prostate cancer, but its advantage over PCA3 after prostate massage has not been shown.
About the authors
A. A. Musaelyan
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: a.musaelyan8@gmail.com
ORCID iD: 0000-0002-7570-2256
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationV. D. Nazarov
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Email: nazarov19932@mail.ru
ORCID iD: 0000-0002-9354-8790
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationS. V. Lapin
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Email: svlapin@mail.ru
ORCID iD: 0000-0002-4998-3699
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationO. N. Pavlova
TestGen
Email: casiopeya13@mail.ru
9 44th Inzhenernyy Proyezd, Ulyanovsk 432072
Russian FederationD. A. Viktorov
TestGen
9 44th Inzhenernyy Proyezd, Ulyanovsk 432072
Russian FederationА. N. Toropovsky
TestGen
9 44th Inzhenernyy Proyezd, Ulyanovsk 432072
Russian FederationA. G. Boriskin
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Email: flounder@yandex.ru
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationS. A. Reva
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Email: sgreva79@mail.ru
ORCID iD: 0000-0001-5183-5153
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationS. B. Petrov
I.P Pavlov First Saint-Petersburg State Medical University, Ministry of Health of Russia
Email: sgreva79@mail.ru
6—8 L’vaTolstogo St., Saint-Petersburg 197722
Russian FederationReferences
- Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. doi: 10.3322/caac.21492.
- Duffy M.J. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med 2020;58(3):326-39. DOI: https://doi.org/10.1515/cclm-2019-0693.
- Van Hoof A., Bunn W., Klein A., Albala D. Role of molecular diagnostics in prostate cancer. Surg Proced Core Urol Trainees 2018:151-77. doi: 10.1007/978-3-319-57442-4_17.
- Kearns J.T., Lin D.W. Improving the specificity of PSA screening with serum and urine markers. Curr Urol Rep 2018;19(10):80. doi: 10.1007/s11934-018-0828-6.
- Tomlins S.A., Aubin S.M.J., Siddiqui J. et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.
- Yang Z., Yu L., Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016;28(1):65-71. doi: 10.3978/j.issn.1000-9604.2016.01.05.
- Koo K.M., Mainwaring P.N., Tomlins S.A., Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol 2019;16(5):302-17. doi: 10.1038/s41585-019-0178-2.
- Hendriks R.J., van Oort I.M., Schalken J.A. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20(1):12-9. doi: 10.1038/pcan.2016.59.
- Raja N., Russell C.M., George A.K. Urinary markers aiding in the detection and risk stratification of prostate cancer. Transl Androl Urol 2018;7(Suppl 4):S436-42. doi: 10.21037/tau.2018.07.01.
- Hessels D., Schalken J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6(5):255-61. doi: 10.1038/nrurol.2009.40.
- Toropovskiy A.N., Nikitin A.G., Gordiev M.G. et al. Results of testing a kit of reagents for detecting mRNA of the PCA3 gene and determining the level of its expression by a two-step RT-PCR-RT (Prosta-Test) method for diagnosing prostate cancer in vitro in clinical practice. Vestnik medicinskogo instituta “REAVIZ” = Bulletin of the Medical Institute “REAVIZ” 2018;(1):126–36. (In Russ.).
- Mottet N., Bastian P., Bellmunt J. et al. EAU-EANM-ESTRO-ESUR-SIOG: Guidelines on Prostate Cancer. Eur Assoc Urol 2020.
- Sokoll L.J., Ellis W., Lange P. et al. A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accu¬racy. Clin Chim Acta 2008;389(1-2):1-6. doi: 10.1016/j.cca.2007.11.003.
- Paliksa S., Gagilas J., Lopeta M. et al. Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage. Eur Urol 2019;18:e2427-8. doi: 10.1016/S1569-9056(19)32142-6.
- Cui Y., Cao W., Li Q. et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 2016;6:25776. doi: 10.1038/srep25776.
- Apolikhin O.I., Sivkov A.V., Efremov G.D. et al. The first Russian experience of using PCA3 and TMPRSS2-ERG for prostate cancer diagnosis. Experimental’naya klinicheskaya urologiya = Experimental Clinical Urology 2015;(2):30-5. (In Russ.).
Supplementary files
